

# EARLY-PHASE ONCOLOGY

## CLINICAL RESEARCH LANDSCAPE AND CRO ENABLERS (2025)

**#DYK**  
Did you know?

Global early-phase oncology expands with targeted therapies, immuno-therapies, and next-generation precision modalities.



**Early-phase** trials account for **~30%** of 10,000 global **oncology studies**.



**3,800+** trials active or planned, evaluating **3,500+** unique drugs.




Trial activity surged from **~50 (2017)** to **>780 (2024)**.



Top cancers: **NSCLC, breast, leukemia, colorectal, and pancreatic**.

### Contributions by Region



- Biomarker-driven designs, and biologically informed dosing are accelerating early-phase oncology development.
- Expert CRO partnerships ensure adaptive execution, regulatory accuracy, and global development success.



Early-phase oncology shaped by targeted small molecules, biologics, vaccines, and cell & gene therapies.



Novel targets—**KRAS, WRN, GPCRs,** and immune checkpoints drive precision oncology.



Adaptive, biomarker-driven, and decentralized trial designs accelerate development.



FDA's Project Optimus advances biologically informed dosing, ensuring patient-centric, evidence-based trials.